---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-25-108426"
form_type: "8-K"
ticker: "LXEO"
cik: "0001907108"
company_name: "Lexeo Therapeutics, Inc."
filed_at: "2025-08-14T23:59:59+00:00"
generated_at: "2026-05-17T13:30:31.712939+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Lexeo reports Q2 net loss $26.1M, advances LX2006 with Breakthrough Therapy, appoints new CFO

## Summary
- Net loss $26.1M ($0.60/sh) vs $21.2M ($0.64/sh) in Q2 2024; cash $152.5M expected to fund operations into 2028.
- LX2006 granted FDA Breakthrough Therapy designation based on interim data; registrational study expected early 2026.
- Eight participants dosed in Phase I/II HEROIC-PKP2 trial of LX2020; interim data update expected H2 2025.
- Closed $80M equity financing in May 2025; strategic partnership for non-viral RNA cardiac therapies.
- Louis Tamayo appointed CFO effective Aug 15, 2025, succeeding Kyle Rasbach.

## SEC filing metadata
- accession: 0000950170-25-108426
- form_type: 8-K
- ticker: LXEO
- cik: 0001907108
- company_name: Lexeo Therapeutics, Inc.
- filed_at: 2025-08-14T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 5.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1907108/000095017025108426/0000950170-25-108426-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1907108/000095017025108426/lxeo-20250814.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-25-108426
- JSON: https://secwatch.observer/filing/0000950170-25-108426.json
- Plain text: https://secwatch.observer/filing/0000950170-25-108426.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.